416-578-2659
timryan@neuraloutcomes.com

AccountCart

Skip to content
Neural Outcomes Consulting Inc.
  • About Us
    • Our Vision
    • Our Team
    • Partners
    • Scientific Advisory Council
    • Media & Communications
  • Services
    • What We Do
    • Clinical Consultations
  • Products
  • Research
  • Teaching & Education
  • Licensing
  • eStore
    • GRASSP Products
    • Outcome Measures
    • Medical Devices
    • Training & Education
  • My Account
  • Shop
  • Cart
  • Contact Us
  • About Us
    • Our Vision
    • Our Team
    • Partners
    • Scientific Advisory Council
    • Media & Communications
  • Services
    • What We Do
    • Clinical Consultations
  • Products
  • Research
  • Teaching & Education
  • Licensing
  • eStore
    • GRASSP Products
    • Outcome Measures
    • Medical Devices
    • Training & Education
  • My Account
  • Shop
  • Cart
  • Contact Us

CMSA Licensing Application

Chedoke-McMaster Stroke Assessment License Application Form

This application form must be filled out to obtain a license for the Chedoke-McMaster Stroke Assessment

Step 1 of 10

10%

IMPORTANT: A fully executed License Agreement must be in place before any use of GRASSP begins. Submission of this form does not constitute a license. Retroactive licensing is not available. All fields marked * are mandatory.

IMPORTANT: A fully executed CMSA License Agreement must be in place before any use of the Chedoke-McMaster Stroke Assessment (CMSA) begins. Submission of this application does not constitute a license. Retroactive licensing is not available. All fields marked with an asterisk (*) are mandatory.

This application asks you to describe your intended use of CMSA, disclose all funding sources and any commercial or regulatory involvement, and provide supporting documentation relevant to your proposed use.

Please complete the Intended Use and License Classification sections carefully: if your use involves more than one activity, organization, funding source or potential commercial or regulatory application, you must disclose all relevant information. The application recommends a preliminary license classification based on your responses. NOCI reviews each submission and makes the final determination.

Please complete this application in full. Incomplete applications will not be processed and will be returned to you. Processing time is 10–15 business days from receipt of a complete application, including all required supporting documents.

All fields marked with an asterisk (*) are mandatory. For questions about license eligibility, fee structures or data-sharing arrangements, contact NOCI before submitting your application, rather than after.

Questions: timryan@neuraloutcomes.com

Your Name(Required)
Your Email Address(Required)
Which item(s) do you need a license for?(Required)
Type N/A if the same as legal name
Organization Address(Required)
Type of organization if you selected ‘Other’ in previous question
Are you the licensing liaison?(Required)
Licensing Liason's Name(Required)
The Licensing Liaison’s title
Are you the Principal Investigator or Clinical Lead?(Required)
Principal Investigor or Clinical Lead's Name(Required)
Is this study's Lead Sponsor, or its Funder Type on ClinicalTrials.gov, classified as Industry (a pharmaceutical, biotech, medical device, or other commercial company) — rather than NIH, another federal agency, or an academic/institutional sponsor?(Required)
Many grant-funded, publicly funded, or academic studies are also required to register on ClinicalTrials.gov, but are classified under Funder Type as NIH, Other U.S. Federal Agency, or Other — not Industry. Select ‘Yes’ only if the trial’s registered sponsor or funder is a commercial/industry entity.
Is any commercial or industry entity (pharma, device, biotech, CRO) a sponsor, co-sponsor, or funder of this study or program?(Required)
Will data from this use be submitted, or is it possible it could be submitted at any point, to any regulatory authority (e.g., Health Canada, FDA, EMA, TGA)?(Required)
Does the named PI/Clinical Lead hold any financial interest (equity, royalties, consulting fees, or advisory role) in any commercial entity that may benefit from the results?(Required)
Is your organization a publicly funded single-payer health system, where no patients are charged for any services related to this use?(Required)
Does your organization's structure include any private, hybrid, or insurance-covered patients, or any for-profit entity in the corporate structure?(Required)
Is the sole output of this work a peer-reviewed publication (no other output type)?(Required)

Recommended Category

C — Single-Payer Site

Based on your answers, your intended use appears to fall under this category (waived, subject to audit). This is because your organization operates within a publicly funded single-payer system with no patients charged, no commercial sponsor, and no research or regulatory involvement. Annual re-attestation will be required. Please confirm this category below.

Recommended Category

D — Multi-Payer Site

Based on your answers, your intended use appears to fall under this category (annual fee based on organization size). This is because your organization’s structure includes private, hybrid, or insurance-covered patients, or a for-profit entity, without a research, commercial sponsorship, or regulatory component. Please confirm this category below.

Recommended Category

A — Academic

Based on your answers, your intended use appears to fall under this category (USD $1,000 per study if data is shared, or USD $1,500 per study if data is not shared). This is because the sole output of this work is peer-reviewed publication, with no commercial sponsor, no regulatory submission, and no investigator financial interest. Please confirm this category below.

No Clear Match

Your answers don’t clearly match one of the four license categories based on the criteria above. This can happen with unusual or mixed-use situations. Please select the category you believe is the closest fit below, and describe your reasoning in the field that will appear. NOCI will confirm the correct category during review before any License Agreement is executed. If you’re unsure, contact NOCI directly before submitting: timryan@neuraloutcomes.com

Recommended Category

B — Clinical Trial / Commercial

Based on your answers, your intended use appears to fall under Category B — Clinical Trial / Commercial (USD $50 per administration, plus translation fees if applicable). This is because you indicated an industry-sponsored trial, a commercial or industry sponsor, potential regulatory use, or a financial interest held by the Principal Investigator or Clinical Lead. Please confirm this category below.

Confirm your license category(Required)
You indicated this is a registered clinical trial, which typically requires Category B. Since you selected a different category, please explain your reasoning below.
You indicated a commercial or industry sponsor is involved in this work, which typically requires Category B. Since you selected a different category, please explain your reasoning below.
You indicated potential regulatory submission (now or in the future), which typically requires Category B. Since you selected a different category, please explain your reasoning below.
You indicated the named PI or Clinical Lead holds a financial interest in a commercial entity that may benefit from results, which typically requires Category B. Since you selected a different category, please explain your reasoning below.
You indicated your organization’s structure includes private, hybrid, or insurance-covered patients, or a for-profit entity, which typically requires Category D rather than Category C. Since you selected Category C, please explain your reasoning below.
By typing your name below and clicking Submit, you agree that this constitutes your electronic signature and has the same legal effect as a handwritten signature. You confirm that you have the authority to bind your organization to the terms of this License Agreement, and you consent to conduct this transaction electronically.
Declaration of Intended Use
I, the undersigned authorized representative of the above-named organization, hereby declare that: 1. The license category selected is accurate and complete as of the date of this application. 2. All known or foreseeable uses of Chedoke-McMaster Stroke Assessment data have been disclosed. 3. All funding sources, commercial relationships, and conflicts of interest have been fully disclosed. 4. Any use beyond the licensed category will require prior written approval from Neural Outcomes Consulting, Inc. and may require payment of additional fees. 5. Neural Outcomes Consulting, Inc. will be notified in writing within 14 calendar days of any material change in scope, use, funding, sponsorship, patient volume, or regulatory intent. 6. I understand that a knowingly false Declaration of Intended Use constitutes fraudulent misrepresentation, voids the license ab initio, and may result in statutory damages under the Copyright Act (Canada), R.S.C. 1985, c. C-42. 7. An annual usage report will be submitted to Neural Outcomes Consulting, Inc. by January 31st of each year, covering administration volume, use context, and any organizational changes in the prior calendar year. SIGNING THE CHEDOKE-MCMASTER STROKE ASSESSMENT LICENSE APPLICATION FORM IMPLIES YOUR ACCEPTANCE OF THIS DOCUMENT AS A LEGAL CONTRACT between Neural Outcomes Consulting, Inc./[RIGHTS HOLDER] and you. This License Agreement shall be governed by the laws of the Province of Ontario and the federal laws of Canada. Any dispute shall be resolved in the courts of Ontario, Canada.
Electronic Signature
  • Our Team
  • Services2
  • GRASSP Licensing
  • Scientific Advisory Council
  • Globalization
  • Research
  • Neural Outcomes Portal
  • Neural Outcomes e-Learning
  • Teaching and Education
  • Contact Us

skr@neuraloutcomes.com
416-578-2659

Sign up for Newsletter ››

Proudly powered by WordPress | Theme: UnderStrap Child by understrap.com. (Version: 0.3.2)